Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

Class:IdLiteratureReference:9852956
_displayNameEGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
_timestamp2023-11-08 18:53:55
author[Person:9852955] Uribe, Mary Luz
[Person:9852950] Marrocco, Ilaria
[Person:182999] Yarden, Y
created[InstanceEdit:9852952] Orlic-Milacic, Marija, 2023-11-08
journalCancers (Basel)
pubMedIdentifier34206026
titleEGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
volume13
year2021
(literatureReference)[Pathway:177929] Signaling by EGFR [Homo sapiens]
[Summation:188591] The epidermal growth factor receptor (EGFR) is one member of...
[Change default viewing format]
No pathways have been reviewed or authored by EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance (9852956)